JP2021526525A5 - - Google Patents

Info

Publication number
JP2021526525A5
JP2021526525A5 JP2020566845A JP2020566845A JP2021526525A5 JP 2021526525 A5 JP2021526525 A5 JP 2021526525A5 JP 2020566845 A JP2020566845 A JP 2020566845A JP 2020566845 A JP2020566845 A JP 2020566845A JP 2021526525 A5 JP2021526525 A5 JP 2021526525A5
Authority
JP
Japan
Prior art keywords
dose
adc
here
patient
substituted
Prior art date
Application number
JP2020566845A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019234694A5 (https=
JP2021526525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054748 external-priority patent/WO2019234694A2/en
Publication of JP2021526525A publication Critical patent/JP2021526525A/ja
Publication of JPWO2019234694A5 publication Critical patent/JPWO2019234694A5/ja
Publication of JP2021526525A5 publication Critical patent/JP2021526525A5/ja
Priority to JP2024095931A priority Critical patent/JP2024154433A/ja
Pending legal-status Critical Current

Links

JP2020566845A 2018-06-07 2019-06-07 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法 Pending JP2021526525A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024095931A JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862682154P 2018-06-07 2018-06-07
US62/682,154 2018-06-07
US201962841702P 2019-05-01 2019-05-01
US62/841,702 2019-05-01
PCT/IB2019/054748 WO2019234694A2 (en) 2018-06-07 2019-06-07 Therapeutic methods using antibody drug conjugates (adcs)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024095931A Division JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Publications (3)

Publication Number Publication Date
JP2021526525A JP2021526525A (ja) 2021-10-07
JPWO2019234694A5 JPWO2019234694A5 (https=) 2022-06-14
JP2021526525A5 true JP2021526525A5 (https=) 2022-06-14

Family

ID=68769968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566845A Pending JP2021526525A (ja) 2018-06-07 2019-06-07 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
JP2024095931A Pending JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024095931A Pending JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Country Status (7)

Country Link
US (2) US20210283267A1 (https=)
EP (1) EP3801635A4 (https=)
JP (2) JP2021526525A (https=)
CN (1) CN112566671A (https=)
AU (1) AU2019283654A1 (https=)
CA (1) CA3101943A1 (https=)
WO (1) WO2019234694A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
JP2022529727A (ja) * 2019-04-24 2022-06-23 マジェンタ セラピューティクス インコーポレイテッド Ａｎｔｉ－ｃｄ１１７ とその使用
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
GB202004263D0 (en) * 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304721A1 (en) * 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
FI3656869T4 (fi) * 2014-08-26 2025-06-04 Univ Leland Stanford Junior Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
JP6668345B2 (ja) * 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
CA2984892A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
US10464969B2 (en) * 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3045592A1 (en) * 2016-12-21 2018-06-28 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン， インコーポレイテッド 抗ｃｄ３３イムノコンジュゲート投与計画

Similar Documents

Publication Publication Date Title
JP2021526525A5 (https=)
AU2021225125B9 (en) Antibody drug conjugate loaded with binary toxins and its application
JP5314590B2 (ja) カンプトテシン結合部分
KR102459469B1 (ko) 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
TWI362934B (en) Phosphonate analogs of hiv inhibitor compounds
JP2020506176A5 (https=)
ES2931923T3 (es) Inmunoconjugados con una enlace intracelularmente escindible
US20230295346A1 (en) Prodruggable antibodies, prodrugs thereof, and methods of use and making
HUE027549T2 (hu) Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
JP2010516675A (ja) 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
PT1644412E (pt) Fragmentos de anticorpos fab modificados
CN107148281A (zh) 结合cxcr5的抗原结合蛋白
JP2018509394A5 (https=)
CN117157098A (zh) 一种药物组合及其用途
JPWO2019234694A5 (https=)
EA022408B1 (ru) Производные санглиферина и способы их получения
TW202432559A (zh) 一類連接子藥物及其抗體-藥物偶聯物的製備方法和應用
CN1817866A (zh) 一组连有核苷碱基的格尔德霉素衍生物
WO2000067792A1 (fr) Anticorps monoclonal dirige contre les cellules de carcinome renal humain
US11717540B2 (en) Modified immune cells and uses thereof
EP4610267A1 (en) Cyclic dinucleotides and conjugates thereof with antibodies
HK40085783A (en) Antibody drug conjugate loaded with double toxins and application thereof
Moore et al. Quilty lesion FOXP3+ and TGF-Beta+ Regulatory T-Cells are associated with acceptance of heart allografts
Zuckermann et al. Peri-Operative Extracorporeal Photopheresis in High Risk Patients after Heart Transplantation
CN120965552A (zh) 基于苯醌结构的连接子和抗体偶联药物及它们的用途